Effect of high-dose intravenous vitamin C on inflammation in cancer patients

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Mikirova, Nina ^a   Casciari, Joseph ^a   Rogers, Andrea ^a   Taylor, Paul ^a  

^a Riordan Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; EOTAXIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 8; PROSTATE SPECIFIC ANTIGEN; RITUXIMAB; TAMOXIFEN; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; INFLAMMATION; LUNG CANCER; MALE; PANCREAS CANCER; PROGNOSIS; PROSTATE CANCER; SKIN CANCER; THYROID CANCER; TUMOR MICROENVIRONMENT;

ASCORBIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFLAMMATION; NEOPLASMS;

EID: 84865966698     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-189     Document Type: Article

References (84)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-867. 10.1038/nature01322, 2803035, 12490959.
2. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217. 10.1016/j.ccr.2005.02.013, 15766659.
3. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003, 3:276-285. 10.1038/nrc1046, 12671666.
4. Bartsch H, Nair J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch Surg 2006, 391:499-510. 10.1007/s00423-006-0073-1, 16909291.
5. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6:24-37. 10.1038/nrc1782, 16397525.
6. Hussain SP, Harris CC. Inflammation and cancer: An ancient link with novel potentials. Int J Cancer 2007, 121:2373-2380. 10.1002/ijc.23173, 17893866.
7. Lu H, Ouyang W, Huang C. Inflammation, a Key Event in Cancer Development. Mol Cancer Res 2006, 4:221-233. 10.1158/1541-7786.MCR-05-0261, 16603636.
8. Macarthur M, Hold GL, El-Omar EM. Inflammation and cancer. II. Role of chronic inflammation and cytokine polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 2004, 286:G515-G520. 10.1152/ajpgi.00475.2003, 15010360.
9. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9:239-252. 10.1038/nrc2618, 3251309, 19279573.
10. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Eng J Med 2003, 348:203-213.
11. Dunn G, Bruce A, Ikeda H, Old L, Schreiber R. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998. 10.1038/ni1102-991, 12407406.
12. Brigati C, Noonan DM, Albini A, Benelli R. Tumors and inflammatory infiltrates: friends or foes?. Clin Exp Metastasis 2002, 19:247-258. 10.1023/A:1015587423262, 12067205.
13. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009, 15:425-430. 10.1158/1078-0432.CCR-08-0149, 19147746.
14. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010, 6:149-163. Review, 10.2217/fon.09.136, 20021215.
15. Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 2002, 7:177-189. 10.1023/A:1020304003704, 12463738.
16. Lin EY, Gouon-Evans V, Nguyen AV, Pollard JW. The macrophage growth factor, CSF-1, in mammary gland development and cancer. J Mammary Gland Biol Neoplasia 2002, 7:147-162. 10.1023/A:1020399802795, 12465600.
17. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006, 6:130-140. 10.1038/nrc1801, 16491072.
18. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009, 12:223-226. Review, 10.1097/MCO.0b013e32832a7902, 19318937.
19. Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther 2010, 87:504-508. 10.1038/clpt.2009.254, 20147899.
20. Wallace JM. Nutritional and botanical modulation of the inflammatory cascade-eicosanoids, cyclooxygenases, and lipoxygenases-as an adjunct in cancer therapy. Integr Cancer Ther 2002, 1:7-37.
21. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer 2006, 13(94):637-641.
22. Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 2006, 94:227-230. 10.1038/sj.bjc.6602922, 2361117, 16404432.
23. Hirschfield GM, Pepys MB. C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM 2003, 96:793-807. 10.1093/qjmed/hcg134, 14566035.
24. Marsik C, Kazemi-Shirazi L, Schickbauer T. C-Reactive Protein and All-Cause Mortality in a Large Hospital-Based Cohort. Clin Chem 2008, 54:343-349. 10.1373/clinchem.2007.091959, 18156283.
25. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993, 91:1351-1357. 10.1172/JCI116336, 288106, 8473487.
26. Vogt B, Fuhrnrohr B, Muller R, Sheriff A. CRP and the disposal of dying cells: consequences for systemic lupus erythematosus and rheumatoid arthritis. Autoimmunity 2007, 40:295-298. 10.1080/08916930701358925, 17516213.
27. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999, 42:23-30. 10.1016/S0162-3109(99)00007-7, 10408362.
28. Marsik C, Kazemi-Shirazi L, Schickbauer T, et al. C-reactive protein and all-cause mortality in large hospital-based cohort. Clin Chem 2008, 54:343-349. 10.1373/clinchem.2007.091959, 18156283.
29. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002, 4:250-255. 10.1007/s11912-002-0023-1, 11937016.
30. McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 2007, 109:933-941. 10.1097/01.AOG.0000257126.68803.03, 17400857.
31. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev 2006, 15:690-695. 10.1158/1055-9965.EPI-05-0708, 16614110.
32. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005, 103:1856-1864. 10.1002/cncr.20976, 15779015.
33. Reichle A, Grassinger J, Bross K, Wilke J, Suedhoff T, Walter B, Wieland WF, Berand A, Andreesen R. C-reactive Protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation. Biomarker Insights 2006, 1:87-98.
34. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004, 291:585-590. 10.1001/jama.291.5.585, 14762037.
35. Shimada H, Nabeya Y, Okazumi S, et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003, 83:248-252. 10.1002/jso.10275, 12884238.
36. Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005, 103:1856-1864. 10.1002/cncr.20976, 15779015.
37. Miyata Y, Koga S, Nishikido M, et al. Diagnostic values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology 2001, 58:161-164. 10.1016/S0090-4295(01)01165-7, 11489689.
38. Kodama J, Miyagi Y, Seki N, et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999, 82:107-110. 10.1016/S0301-2115(98)00227-9, 10192497.
39. Ford ES, Liu S, Mannino DM, Giles WH, Smith SJ. C-reactive protein concentration and concentrations of blood vitamins, carotenoids, and selenium among United States adults. Eur J Clin Nutr 2003, 57(9):1157-1163. 10.1038/sj.ejcn.1601667, 12947436.
40. Halliwell B, Gutteridge JM. Free Radicals in Biology and Medicine 1999, New York: Oxford University Press.
41. Calder PC, Albers R, Antoine JM, et al. Inflammatory disease processes and interactions with nutrition. Br J Nutr 2009, 101(Suppl 1):S1-S45.
42. Mayland CR, Bennett MI, et al. Vitamin C deficiency in cancer patients. Palliat Med 2005, 19:17-20. 10.1191/0269216305pm970oa, 15690864.
43. Härtel C, Strunk T, Bucsky P, Schultz C. Effects of vitamin C on intracytoplasmic cytokine production in human whole blood monocytes and lymphocytes. Cytokines 2004, 27(4-5):101-106.
44. Andrew G, Bowie, O'Neill LAJ. Vitamin C Inhibits NF-kB Activation by TNF Via the Activation of p38 Mitogen-Activated Protein Kinase. The J Immunol 2000, 165:7180-7188.
45. Munoz E, Blazquez MV, Ortiz C, Gomez-Diaz C, Navas P. Role of ascorbate in the activation of NF-kB by tumor necrosis factor-a in T-cells. Biochem J 1997, 325:23. 1218524, 9224625.
46. Bowie AG, Carcamo JM, Pedraza A, Borquez-Qjeda O, Golde DW. Vitamin C suppresses TNFa-induced NFkB activation by inhibiting IkαB phosphorilation. Biochemistry 2002, 41:12995-13002. 10.1021/bi0263210, 12390026.
47. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc. Natl. Acad. Sci. USA 1976, 73:3685-3689. 10.1073/pnas.73.10.3685, 431183, 1068480.
48. Riordan HD, Casciari JJ, González MJ, Riordan NH, Miranda-Massari JR, Taylor P, Jackson JA. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J 2005, 24(4):269-276.
49. Riordan NH, Riordan HRD, Meng X, Li Y, Jackson JA. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Medical hypothesis 1995, 44:213.
50. Casciari JJ, Riordan NH, et al. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fiber in vitro tumors. Br J Cancer 2001, 84:1544-1550. 10.1054/bjoc.2001.1814, 2363673, 11384106.
51. Mikirova NA, Ichim TE, Riordan NH. Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med 2008, 12:6:50.
52. Mikirova NA, Casciari JJ, Riordan NH. Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo. Journal of Angiogenesis Research 2010, 2:2. 10.1186/2040-2384-2-2, 2820478, 20150992.
53. Casciari JJ, Riordan HD, Mirranda-Massara JR, Gonzalez MJ. Effects of high dose ascorbate administration on L-10 tumor growth in guinea pigs. PR Health Sci. J 2005, 24:145-150.
54. Dworacki G, Meidenbauer N, Kuss I, Hoffmann TK, Gooding W, Lotze M, Whiteside TL. Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 2007, 7:947s-957s.
55. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009, 182:5693-5701. 10.4049/jimmunol.0900092, 2833019, 19380816.
56. Baniyash M. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol 2004, 4(9):675-687. 10.1038/nri1434, 15343367.
57. Schmielau J, Nalesnik MA, Finn OJ. Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. Clin cancer research 2001, 17(3 Suppl):933s-939s.
58. Nakagomi H, Peterson M, Magnusson I, Matsuda M, Mellstedt H, Taupin JL, Vivier E, Anderson P. Kiessling R: Decreased expression of the signal transducing z chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993, 53:5610-5612.
59. Gunji Y, Hori S, Aoe T, Asano T, Ochiai T, Isona K, Saito T. High frequency of cancer patients with abnormal assembly of the T cell receptor-CD3 complex in peripheral blood T lymphocytes. Jpn J Cancer Res 1994, 85:1189-1192. 10.1111/j.1349-7006.1994.tb02927.x, 7852180.
60. Nambiar MP, Fisher CU, Enyedy EJ, Warke VG, Kumar A, Tsokos GC. Oxidative stress is involved in the heat stress-induced downregulation of TCR zeta chain expression and TCR/CD3-mediated [Ca(2+)](i) response in human T-lymphocytes. Cell Immunol 2002, 215:151-161. 10.1016/S0008-8749(02)00006-0, 12202152.
61. Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock W, Riordan NH. Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J 2008, 27(1):7-19. Review.
62. Duconge J, Miranda-Massari JR, González MJ, Taylor PR, Riordan HD, Riordan NH, Casciari JJ, Alliston K. Vitamin C pharmacokinetics after continuous infusion in a patient with prostate cancer. Ann Pharmacother 2007, 41(6):1082-1083. 10.1345/aph.1H654, 17519294.
63. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A 2005, 102:13604-13609. 10.1073/pnas.0506390102, 1224653, 16157892.
64. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 2008, 19(11):1969-1974. Erratum in: Ann Oncol. 2008 19(12):2095, 10.1093/annonc/mdn377, 18544557.
65. Ohno S, Ohno Y, Suzuki N, Soma G, Inoue M. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res 2009, 29(3):809-815. Review.
66. StSauver JL, Sarma AV, Jacobson DJ, McGree ME, Lieber MM, Girman CJ, Nehra A, Jacobsen SJ. Associations Between C-Reactive Protein and Benign Prostatic Hyperplasia/Lower Urinary Tract Symptom Outcomes in a Population-based Cohort. Am J Epidemiol 2009, 169:1281-1290. 10.1093/aje/kwp085, 2727252, 19395697.
67. Lin ATL, Chen KK, Chung HJ, Chang SC. The Significance of Plasma C-reactive Protein in Patients With Elevated Serum Prostate-specific Antigen Levels. Urological Science 2010, 21(2):88-92.
68. Eklund CM, Tammela TLJ, Schleutker J, Hurme M. C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk. Br J Cancer 2009, 100:1846-1851. 10.1038/sj.bjc.6605081, 2714238, 19436291.
69. Sauver JL, Jacobsen SJ. Inflammatory mechanisms associated with prostatic inflammation and lower urinary tract symptoms. Curr Prostate Rep 2008, 6:67-73. 10.1007/s11918-008-0011-5, 2757322, 19809538.
70. Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol 1979, 121(6):755-760.
71. Di Silverio F, Gentile V, De Matteis A, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003, 43(2):164-175. 10.1016/S0302-2838(02)00548-1, 12565775.
72. Gerstenbluth RE, Seftel AD, MacLennan GT, et al. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol 2002, 167(5):2267-2270. 10.1016/S0022-5347(05)65140-3, 11956490.
73. Roehrborn C, Kaplan SA, Noble WD, et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results of the MTOP study. J Urol 2005, 173:204. 10.1097/01.ju.0000147849.80627.41, 15592076.
74. Apte RN, Krelin Y, Song X, et al. Effects of microenvironment- and malignant cell-derived interleukin- 1 in carcinogenesis, tumour invasiveness and tumour-host interactions. Eur J Cancer 2006, 42:751-759. 10.1016/j.ejca.2006.01.010, 16530403.
75. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003, 100:2645-2650. 10.1073/pnas.0437939100, 151394, 12598651.
76. Wu Y, Zhou BP. Inflammation. A driving force speeds cancer metastasis. Cell Cycle 2009, 8(20):3267-3273. 10.4161/cc.8.20.9699, 19770594.
77. Rosen EM, Goldberg ID, Liu D, et al. Tumor necrosis factor stimulates epithelial tumor cell motility. Cancer Res 1991, 51:5315-5321.
78. Arnott CH, Scott KA, Moore RJ, et al. Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 2004, 23:1902-1910. 10.1038/sj.onc.1207317, 14661063.
79. Egberts JH, Cloosters V, Noack A, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2008, 68:1443-1450. 10.1158/0008-5472.CAN-07-5704, 18316608.
80. Kulbe H, Thompson R, Wilson JL, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting networkin epithelial ovarian cancer cells. Cancer Res 2007, 67:585-592. 10.1158/0008-5472.CAN-06-2941, 2679985, 17234767.
81. Murooka TT, Ward SE, Fish EN. Chemokines and cancer. Cancer Treat Res 2005, 126:15-44. 10.1007/0-387-24361-5_2, 16209061.
82. Rollins BJ. Inflammatory chemokines in cancer growth and progression. Eur J Cancer 2006, 42:760-767. 10.1016/j.ejca.2006.01.002, 16510278.
83. Zlotnik A. Chemokines and cancer. Int J Cancer 2006, 119:2026-2029. 10.1002/ijc.22024, 16671092.
84. Salcedo R, Young HA, Ponce ML, et al. Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. J Immunol 2001, 166:7571-7578.